Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 Feb;52(2):89–94. doi: 10.1136/jcp.52.2.89

Recent advances in antiviral therapy.

D Kinchington 1
PMCID: PMC501047  PMID: 10396233

Abstract

In the early 1980s many institutions in Britain were seriously considering whether there was a need for specialist departments of virology. The arrival of HIV changed that perception and since then virology and antiviral chemotherapy have become two very active areas of bio-medical research. Cloning and sequencing have provided tools to identify viral enzymes and have brought the day of the "designer drug" nearer to reality. At the other end of the spectrum of drug discovery, huge numbers of compounds for screening can now be generated by combinatorial chemistry. The impetus to find drugs effective against HIV has also stimulated research into novel treatments for other virus infections including herpesvirus, respiratory infections, and hepatitis B and C viruses. The need to understand the function of the immune system during HIV infection has brought virologists and immunologists together into new partnerships. The huge increase in activity in antiviral research is reflected in the frequency with which these drugs are now being licensed: in 1985 there were two licensed antiviral drugs for systemic use. Since then approximately 20 compounds have been licensed and more are being submitted to the regulatory authorities on a regular basis.

Full text

PDF
89

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartenschlager R., Lohmann V., Wilkinson T., Koch J. O. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol. 1995 Dec;69(12):7519–7528. doi: 10.1128/jvi.69.12.7519-7528.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beutner K. R., Friedman D. J., Forszpaniak C., Andersen P. L., Wood M. J. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995 Jul;39(7):1546–1553. doi: 10.1128/aac.39.7.1546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bischofberger N., Hitchcock M. J., Chen M. S., Barkhimer D. B., Cundy K. C., Kent K. M., Lacy S. A., Lee W. A., Li Z. H., Mendel D. B. 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother. 1994 Oct;38(10):2387–2391. doi: 10.1128/aac.38.10.2387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bodenheimer H. C., Jr, Lindsay K. L., Davis G. L., Lewis J. H., Thung S. N., Seeff L. B. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997 Aug;26(2):473–477. doi: 10.1002/hep.510260231. [DOI] [PubMed] [Google Scholar]
  5. Carpenter C. C., Fischl M. A., Hammer S. M., Hirsch M. S., Jacobsen D. M., Katzenstein D. A., Montaner J. S., Richman D. D., Saag M. S., Schooley R. T. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997 Jun 25;277(24):1962–1969. [PubMed] [Google Scholar]
  6. D'Aquila R. T., Hughes M. D., Johnson V. A., Fischl M. A., Sommadossi J. P., Liou S. H., Timpone J., Myers M., Basgoz N., Niu M. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med. 1996 Jun 15;124(12):1019–1030. doi: 10.7326/0003-4819-124-12-199606150-00001. [DOI] [PubMed] [Google Scholar]
  7. Danner S. A., Carr A., Leonard J. M., Lehman L. M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995 Dec 7;333(23):1528–1533. doi: 10.1056/NEJM199512073332303. [DOI] [PubMed] [Google Scholar]
  8. Darby G. The acyclovir legacy: its contribution to antiviral drug discovery. J Med Virol. 1993;Suppl 1:134–138. doi: 10.1002/jmv.1890410526. [DOI] [PubMed] [Google Scholar]
  9. Gorochov G., Neumann A. U., Kereveur A., Parizot C., Li T., Katlama C., Karmochkine M., Raguin G., Autran B., Debré P. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med. 1998 Feb;4(2):215–221. doi: 10.1038/nm0298-215. [DOI] [PubMed] [Google Scholar]
  10. Gottlieb A. A., Gottlieb M. S. Development of immunomodulators for treatment of HIV infection. Lymphology. 1990 Jun;23(2):98–101. [PubMed] [Google Scholar]
  11. Hammer S. M., Katzenstein D. A., Hughes M. D., Gundacker H., Schooley R. T., Haubrich R. H., Henry W. K., Lederman M. M., Phair J. P., Niu M. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996 Oct 10;335(15):1081–1090. doi: 10.1056/NEJM199610103351501. [DOI] [PubMed] [Google Scholar]
  12. Hayden F. G., Treanor J. J., Betts R. F., Lobo M., Esinhart J. D., Hussey E. K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA. 1996 Jan 24;275(4):295–299. [PubMed] [Google Scholar]
  13. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  14. Innaimo S. F., Seifer M., Bisacchi G. S., Standring D. N., Zahler R., Colonno R. J. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997 Jul;41(7):1444–1448. doi: 10.1128/aac.41.7.1444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kim C. U., Lew W., Williams M. A., Liu H., Zhang L., Swaminathan S., Bischofberger N., Chen M. S., Mendel D. B., Tai C. Y. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997 Jan 29;119(4):681–690. doi: 10.1021/ja963036t. [DOI] [PubMed] [Google Scholar]
  16. Kovacs J. A., Vogel S., Albert J. M., Falloon J., Davey R. T., Jr, Walker R. E., Polis M. A., Spooner K., Metcalf J. A., Baseler M. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med. 1996 Oct 31;335(18):1350–1356. doi: 10.1056/NEJM199610313351803. [DOI] [PubMed] [Google Scholar]
  17. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  18. Littler E., Stuart A. D., Chee M. S. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature. 1992 Jul 9;358(6382):160–162. doi: 10.1038/358160a0. [DOI] [PubMed] [Google Scholar]
  19. Main J., Brown J. L., Howells C., Galassini R., Crossey M., Karayiannis P., Georgiou P., Atkinson G., Thomas H. C. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat. 1996 Jul;3(4):211–215. doi: 10.1111/j.1365-2893.1996.tb00098.x. [DOI] [PubMed] [Google Scholar]
  20. Mellors J. W., Kingsley L. A., Rinaldo C. R., Jr, Todd J. A., Hoo B. S., Kokka R. P., Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995 Apr 15;122(8):573–579. doi: 10.7326/0003-4819-122-8-199504150-00003. [DOI] [PubMed] [Google Scholar]
  21. Merluzzi V. J., Hargrave K. D., Labadia M., Grozinger K., Skoog M., Wu J. C., Shih C. K., Eckner K., Hattox S., Adams J. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990 Dec 7;250(4986):1411–1413. doi: 10.1126/science.1701568. [DOI] [PubMed] [Google Scholar]
  22. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. O'Brien W. A., Hartigan P. M., Martin D., Esinhart J., Hill A., Benoit S., Rubin M., Simberkoff M. S., Hamilton J. D. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996 Feb 15;334(7):426–431. doi: 10.1056/NEJM199602153340703. [DOI] [PubMed] [Google Scholar]
  25. Pakker N. G., Notermans D. W., de Boer R. J., Roos M. T., de Wolf F., Hill A., Leonard J. M., Danner S. A., Miedema F., Schellekens P. T. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med. 1998 Feb;4(2):208–214. doi: 10.1038/nm0298-208. [DOI] [PubMed] [Google Scholar]
  26. Pauwels R., Andries K., Debyser Z., Van Daele P., Schols D., Stoffels P., De Vreese K., Woestenborghs R., Vandamme A. M., Janssen C. G. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1711–1715. doi: 10.1073/pnas.90.5.1711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Perelson A. S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., Markowitz M., Ho D. D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997 May 8;387(6629):188–191. doi: 10.1038/387188a0. [DOI] [PubMed] [Google Scholar]
  28. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586. doi: 10.1126/science.271.5255.1582. [DOI] [PubMed] [Google Scholar]
  29. Perry C. M., Wagstaff A. J. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs. 1995 Aug;50(2):396–415. doi: 10.2165/00003495-199550020-00011. [DOI] [PubMed] [Google Scholar]
  30. Rhodes J., Chen H., Hall S. R., Beesley J. E., Jenkins D. C., Collins P., Zheng B. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature. 1995 Sep 7;377(6544):71–75. doi: 10.1038/377071a0. [DOI] [PubMed] [Google Scholar]
  31. Roberts N. A., Martin J. A., Kinchington D., Broadhurst A. V., Craig J. C., Duncan I. B., Galpin S. A., Handa B. K., Kay J., Kröhn A. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990 Apr 20;248(4953):358–361. doi: 10.1126/science.2183354. [DOI] [PubMed] [Google Scholar]
  32. Shaw T., Mok S. S., Locarnini S. A. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology. 1996 Nov;24(5):996–1002. doi: 10.1002/hep.510240504. [DOI] [PubMed] [Google Scholar]
  33. Shetty B. V., Kosa M. B., Khalil D. A., Webber S. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 1996 Jan;40(1):110–114. doi: 10.1128/aac.40.1.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Spector S. A., McKinley G. F., Lalezari J. P., Samo T., Andruczk R., Follansbee S., Sparti P. D., Havlir D. V., Simpson G., Buhles W. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1996 Jun 6;334(23):1491–1497. doi: 10.1056/NEJM199606063342302. [DOI] [PubMed] [Google Scholar]
  35. St Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991 Sep 27;253(5027):1557–1559. doi: 10.1126/science.1716788. [DOI] [PubMed] [Google Scholar]
  36. Staszewski S., Miller V., Rehmet S., Stark T., De Crée J., De Brabander M., Peeters M., Andries K., Moeremans M., De Raeymaeker M. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS. 1996 May;10(5):F1–F7. doi: 10.1097/00002030-199605000-00001. [DOI] [PubMed] [Google Scholar]
  37. Stein D. S., Fish D. G., Bilello J. A., Preston S. L., Martineau G. L., Drusano G. L. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 1996 May;10(5):485–492. doi: 10.1097/00002030-199605000-00006. [DOI] [PubMed] [Google Scholar]
  38. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653–5656. doi: 10.1073/pnas.90.12.5653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Touraine J. L., Sanhadji K., Zerhouni B., Livrozet J. M. Rationale for a combined use of antiretroviral and immunomodulatory therapies in HIV infection. Int J Immunopharmacol. 1991;13 (Suppl 1):43–48. doi: 10.1016/0192-0561(91)90123-o. [DOI] [PubMed] [Google Scholar]
  40. Wagstaff A. J., Faulds D., Goa K. L. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994 Jan;47(1):153–205. doi: 10.2165/00003495-199447010-00009. [DOI] [PubMed] [Google Scholar]
  41. Wagstaff A. J., Faulds D., Goa K. L. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994 Jan;47(1):153–205. doi: 10.2165/00003495-199447010-00009. [DOI] [PubMed] [Google Scholar]
  42. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES